Cargando…

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study

BACKGROUND: When type 2 diabetes is suboptimally controlled with basal insulin, prandial insulin injections are commonly added (i.e., a basal-bolus insulin regimen), which can increase treatment burden and hypoglycemia risk. The once-daily injectable iGlarLixi is an alternative treatment. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantalone, Kevin M., Heller, Caroline, Lajara, Rosemarie, Lew, Elisheva, Li, Xuan, Dex, Terry, Kilpatrick, C. Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425231/
https://www.ncbi.nlm.nih.gov/pubmed/37583559
http://dx.doi.org/10.2337/ds22-0064
_version_ 1785089792124387328
author Pantalone, Kevin M.
Heller, Caroline
Lajara, Rosemarie
Lew, Elisheva
Li, Xuan
Dex, Terry
Kilpatrick, C. Rachel
author_facet Pantalone, Kevin M.
Heller, Caroline
Lajara, Rosemarie
Lew, Elisheva
Li, Xuan
Dex, Terry
Kilpatrick, C. Rachel
author_sort Pantalone, Kevin M.
collection PubMed
description BACKGROUND: When type 2 diabetes is suboptimally controlled with basal insulin, prandial insulin injections are commonly added (i.e., a basal-bolus insulin regimen), which can increase treatment burden and hypoglycemia risk. The once-daily injectable iGlarLixi is an alternative treatment. METHODS: This retrospective analysis of the U.S. Optum Clinformatics database compared outcomes in adults (≥18 years of age) with type 2 diabetes who previously received basal insulin and were newly initiated on iGlarLixi or basal-bolus insulin therapy. Cohorts were propensity score–matched in a 1:1 ratio on baseline characteristics, and imbalances were adjusted in multivariate analyses. Subgroup analyses were performed for people ≥65 years of age and those with a baseline A1C ≥9%. The primary end point was persistence with therapy at 12 months in the overall population. Secondary end points were treatment adherence, health care resource utilization (HCRU), costs, any hypoglycemia, and A1C change at 12 months. RESULTS: Cohorts each comprised 1,070 participants. Treatment persistence at 12 months was statistically significantly higher for iGlarLixi versus basal-bolus insulin therapy (43.7 vs. 22.3%, hazard ratio 0.51, 95% CI 0.46–0.57, adjusted P <0.001). Adherence was numerically higher for iGlarLixi, and hypoglycemia events, HCRU, and costs were numerically lower for iGlarLixi. A1C reduction from baseline was slightly greater for basal-bolus insulin. Results for both subgroups (≥65 years of age and baseline A1C ≥9%) were similar to those of the overall population. CONCLUSION: In this observational study, initiation of once-daily iGlarLixi versus basal-bolus insulin was associated with higher persistence, lower hypoglycemia, and similar A1C reduction without increasing HCRU or costs regardless of age or A1C. iGlarLixi could be an alternative to basal-bolus insulin, particularly for older adults with type 2 diabetes who require treatment simplification with lower hypoglycemia risk.
format Online
Article
Text
id pubmed-10425231
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-104252312023-08-15 Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study Pantalone, Kevin M. Heller, Caroline Lajara, Rosemarie Lew, Elisheva Li, Xuan Dex, Terry Kilpatrick, C. Rachel Diabetes Spectr Feature Articles BACKGROUND: When type 2 diabetes is suboptimally controlled with basal insulin, prandial insulin injections are commonly added (i.e., a basal-bolus insulin regimen), which can increase treatment burden and hypoglycemia risk. The once-daily injectable iGlarLixi is an alternative treatment. METHODS: This retrospective analysis of the U.S. Optum Clinformatics database compared outcomes in adults (≥18 years of age) with type 2 diabetes who previously received basal insulin and were newly initiated on iGlarLixi or basal-bolus insulin therapy. Cohorts were propensity score–matched in a 1:1 ratio on baseline characteristics, and imbalances were adjusted in multivariate analyses. Subgroup analyses were performed for people ≥65 years of age and those with a baseline A1C ≥9%. The primary end point was persistence with therapy at 12 months in the overall population. Secondary end points were treatment adherence, health care resource utilization (HCRU), costs, any hypoglycemia, and A1C change at 12 months. RESULTS: Cohorts each comprised 1,070 participants. Treatment persistence at 12 months was statistically significantly higher for iGlarLixi versus basal-bolus insulin therapy (43.7 vs. 22.3%, hazard ratio 0.51, 95% CI 0.46–0.57, adjusted P <0.001). Adherence was numerically higher for iGlarLixi, and hypoglycemia events, HCRU, and costs were numerically lower for iGlarLixi. A1C reduction from baseline was slightly greater for basal-bolus insulin. Results for both subgroups (≥65 years of age and baseline A1C ≥9%) were similar to those of the overall population. CONCLUSION: In this observational study, initiation of once-daily iGlarLixi versus basal-bolus insulin was associated with higher persistence, lower hypoglycemia, and similar A1C reduction without increasing HCRU or costs regardless of age or A1C. iGlarLixi could be an alternative to basal-bolus insulin, particularly for older adults with type 2 diabetes who require treatment simplification with lower hypoglycemia risk. American Diabetes Association 2023 2023-03-07 /pmc/articles/PMC10425231/ /pubmed/37583559 http://dx.doi.org/10.2337/ds22-0064 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Feature Articles
Pantalone, Kevin M.
Heller, Caroline
Lajara, Rosemarie
Lew, Elisheva
Li, Xuan
Dex, Terry
Kilpatrick, C. Rachel
Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title_full Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title_fullStr Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title_full_unstemmed Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title_short Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
title_sort initiation of iglarlixi versus basal-bolus insulin in adults with type 2 diabetes advancing from basal insulin therapy: the solicomplex real-world study
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425231/
https://www.ncbi.nlm.nih.gov/pubmed/37583559
http://dx.doi.org/10.2337/ds22-0064
work_keys_str_mv AT pantalonekevinm initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT hellercaroline initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT lajararosemarie initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT lewelisheva initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT lixuan initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT dexterry initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy
AT kilpatrickcrachel initiationofiglarlixiversusbasalbolusinsulininadultswithtype2diabetesadvancingfrombasalinsulintherapythesolicomplexrealworldstudy